Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline

Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, Edward A. Stadtmauer, Thierry Facon, Jean Luc Harousseau, Dina Ben-Yehuda, Sagar Lonial, Hartmut Goldschmidt, Donna Reece, Joan Bladé, Mario Boccadoro, Jamie D. Cavenagh, Anthony L. Boral, Dixie Lee Esseltine, Patrick Y. Wen, Anthony A. Amato, Kenneth C. Anderson, Jesus San Miguel

Research output: Contribution to journalArticlepeer-review

273 Scopus citations

Fingerprint

Dive into the research topics of 'Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline'. Together they form a unique fingerprint.

Keyphrases

Immunology and Microbiology